All posts by Matthias

TRACT Therapeutics, Inc. Receives Orphan-Drug Designation for TRK-001 from the U.S. Food and Drug Administration for the Prevention of Graft Rejection Following Solid Organ Transplantation

CHICAGO (PRWEB) NOVEMBER 19, 2020 TRACT Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company’s investigational candidate, TRK-001, for its potential to prevent graft rejection following solid organ transplantation. TRK-001 is an autologous regulatory T-cell therapy that utilizes a patient’s Continue reading

TRACT Therapeutics, Inc. Launches the TRACT CryoBanking Program™ to Collect and Bank a Patient’s Immune Cells for Future Treatment

May 31, 2016 08:58 AM Central Daylight Time CHICAGO (BUSINESS WIRE) – TRACT Therapeutics, Inc., a biotechnology company developing personalized regulatory Tcell (Treg) therapy, announced today that it has launched the TRACT CryoBanking Program to enable individuals to donate their blood consisting of their immune cells for future treatments as Continue reading

TRACT Therapeutics, Inc. Received FDA Approval for a Phase 2 Trial Using a Patient’s Immune Cells to Prevent Organ Rejection

April 29, 2016 15:07 UTC CHICAGO–(BUSINESS WIRE)– TRACT Therapeutics, Inc., a biotechnology company developing personalized regulatory T-cell (Treg) therapy, announced today that it received Food and Drug Administration (FDA) approval to initiate a Phase 2 clinical trial to investigate the efficacy and safety of its novel therapy for kidney transplant Continue reading